IHP with melphalan and TNF-α performed in patients with metastases of ocular melanoma or leiomyosarcoma showed overall response rates of 50–52% (Lindner et al, 1999; Alexander et al, 2000). This evidence concerns the gene TNF and ocular melanoma.